Skip to main content

Ani Pharmaceuticals Inc

ANIP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001023024

In the last 90 days, Ani Pharmaceuticals Inc insiders filed 0 open-market purchases and 10 sales; 307 institutions reported holding it in 13F filings for Q2 2026, worth $1.90B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Ani Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
10 filings
5 insiders, $1.94M in total
Insiders trading
5
Net value
−$1.94M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Ani Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Ani Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Lalwani NikhilPRESIDENT & CEO339,089Sep 16, 20267
Thoma JeanneDirector26,762Sep 14, 20262
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.73,924Sep 14, 202615
Carey Stephen P.SVP & CFO171,843Sep 1, 202610
Gosebruch Henry ODirector6,662Aug 27, 20261
Gutwerg OriSVP, GENERICS75,534Aug 11, 20267
Haughey ThomasDirector38,878Jun 10, 20261
Tannenbaum Renee PDirector29,514Jun 10, 20262
Pera Antonio RDirector27,017Jun 10, 20261
Leonard Matthew JDirector11,221Jun 10, 20261
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS38,271May 13, 20265
Walsh Patrick DDirector38,432May 13, 20263
Mutz ChristopherHEAD OF RARE DISEASE91,309Mar 13, 20267
Davis KristaSVP, CHIEF HR OFFICER51,946Mar 10, 20266
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS101,056Mar 2, 20262
Gassert ChadSVP - CORP. DEV. & STRATEGY74,916Mar 2, 20264
Marken James G.SVP OPS & PROD DEV117,829Jun 11, 20240
Meridian Venture Partners II LP10% Owner1,819,259Aug 16, 20230
Brown Robert E. JR10% Owner1,819,259Aug 16, 20230
Meridian Venture Partners II, Co.10% Owner1,819,259Aug 16, 20230
Meridian Venture Partners II GP, L.P.10% Owner1,819,259Aug 16, 20230
Nash DavidDirector38,561May 24, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 7, 2021 (view filing)Dec 61 dayHaughey ThomasDirectorPPurchase+2.50K$39.38+$98.5K+9.0%30.2K after
Dec 9, 2021 (view filing)Dec 72 daysPera Antonio RDirectorPPurchase+3.00K$42.26+$126.8K+18.0%19.7K after
Dec 22, 2021 (view filing)Dec 202 daysThoma JeanneDirectorPPurchase+1.07K$46.47+$49.8K+6.4%17.8K after
Mar 21, 2022 (view filing)Mar 174 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSPPurchase+5.00K$27.65+$138.3K+37.1%18.5K after
Mar 21, 2022 (view filing)Mar 174 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSPPurchase+5.00K$27.65+$138.3KNew position5.00K after
Mar 22, 2022 (view filing)Mar 18-214 daysGassert ChadSVP - CORP. DEV. & STRATEGYPPurchase+10.0K$27.51+$275.1K+2.6%393.2K after2 lots
Mar 22, 2022 (view filing)Mar 211 dayWalsh Patrick DDirectorPPurchase+5.00K$27.76+$138.8K+10.3%53.4K after
Mar 23, 2022 (view filing)Mar 212 daysLalwani NikhilPRESIDENT & CEOPPurchase+7.22K$27.69+$200.0K+4.4%169.7K after
Aug 16, 2022 (view filing)Aug 12-154 daysMarken James G.SVP OPS & PROD DEVSSale−18.1K$37.25−$673.0K−13.3%117.6K after2 lots
Dec 2, 2022 (view filing)4:00 PM ETDec 11 dayBrown Robert E. JR and 3 othersDirectorSSale−200.0K$38.50−$7.70M−9.0%2.02M after
Jun 23, 2023 (view filing)Jun 221 dayGassert ChadSVP - CORP. DEV. & STRATEGYSSale−20.0K$51.32−$1.03M−5.1%373.2K after10b5-1
Jun 23, 2023 (view filing)Jun 20-233 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−50.0K$51.70−$2.58M−3.8%1.28M afterAmended4 lots10b5-1
Jul 6, 2023 (view filing)Jul 33 daysGassert ChadSVP - CORP. DEV. & STRATEGYSSale−20.0K$53.43−$1.07M−5.4%353.2K after10b5-1
Jul 18, 2023 (view filing)Jul 14-184 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−26.5K$51.02−$1.35M−2.1%1.26M after3 lots10b5-1
Jul 21, 2023 (view filing)Jul 19-212 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−23.5K$52.02−$1.22M−1.9%1.23M after3 lots10b5-1
Aug 3, 2023 (view filing)Aug 12 daysGassert ChadSVP - CORP. DEV. & STRATEGYSSale−20.0K$51.06−$1.02M−5.7%333.2K after10b5-1
Aug 15, 2023 (view filing)Aug 141 dayPera Antonio RDirectorSSale−3.00K$60.37−$181.1K−8.2%33.6K after10b5-1
Aug 15, 2023 (view filing)Aug 11-154 daysLalwani NikhilPRESIDENT & CEOSSale−68.3K$58.32−$3.98M−16.2%353.4K after2 lots
Aug 16, 2023 (view filing)Aug 142 daysCarey Stephen P.SVP & CFOSSale−17.6K$61.37−$1.08M−10.2%155.8K after
Aug 16, 2023 (view filing)Aug 14-152 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−50.0K$61.35−$3.07M−4.1%1.18M after2 lots10b5-1
Aug 16, 2023 (view filing)8:00 PM ETAug 16Same dayMeridian Venture Partners II LP and 3 others10% OwnerSSale−200.0K$58.50−$11.7M−9.9%1.82M after
Aug 25, 2023 (view filing)Aug 232 daysMarken James G.SVP OPS & PROD DEVSSale−3.93K$63.00−$247.7K−2.9%133.1K after
Aug 25, 2023 (view filing)Aug 232 daysGutwerg OriSVP, GENERICSSSale−15.6K$62.39−$970.9K−20.3%60.9K after2 lots
Aug 30, 2023 (view filing)Aug 28-292 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−50.0K$63.22−$3.16M−4.2%1.13M after2 lots
Sep 5, 2023 (view filing)Sep 14 daysGassert ChadSVP - CORP. DEV. & STRATEGYSSale−20.0K$64.70−$1.29M−6.0%313.2K after10b5-1
Sep 19, 2023 (view filing)Sep 15-194 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−50.0K$61.81−$3.09M−4.4%1.08M after3 lots10b5-1
Oct 3, 2023 (view filing)Oct 21 dayGassert ChadSVP - CORP. DEV. & STRATEGYSSale−20.0K$56.48−$1.13M−6.4%293.2K after10b5-1
Oct 17, 2023 (view filing)Oct 13-164 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−25.0K$57.96−$1.45M−2.3%1.06M after2 lots10b5-1
Oct 19, 2023 (view filing)Oct 17-192 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−25.0K$57.75−$1.44M−2.4%1.03M after3 lots10b5-1
Nov 13, 2023 (view filing)Nov 103 daysMutz ChristopherHEAD OF RARE DISEASESSale−3.00K$52.47−$157.4K−4.5%63.6K after
Nov 14, 2023 (view filing)Nov 131 dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$52.03−$13.0K−0.7%37.5K after10b5-1
Nov 16, 2023 (view filing)Nov 151 dayDavis KristaSVP, CHIEF HR OFFICERSSale−2.62K$53.81−$141.1K−7.4%32.6K after
Nov 20, 2023 (view filing)Nov 14-166 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−37.0K$53.00−$1.96M−3.6%995.6K afterAmended3 lots10b5-1
Nov 20, 2023 (view filing)Nov 173 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−13.0K$51.00−$663.0K−1.3%982.6K after10b5-1
Dec 11, 2023 (view filing)Dec 11Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$49.21−$12.3K−0.7%37.3K after10b5-1
Dec 19, 2023 (view filing)Dec 15-194 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−50.0K$52.55−$2.63M−5.1%932.6K after3 lots10b5-1
Jan 16, 2024 (view filing)Jan 124 daysCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$56.43−$14.1K−0.7%37.0K after10b5-1
Jan 18, 2024 (view filing)Jan 16-182 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−24.8K$55.29−$1.37M−2.7%907.8K after3 lots10b5-1
Jan 23, 2024 (view filing)Jan 19-234 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−25.2K$56.17−$1.42M−2.8%882.6K after3 lots10b5-1
Feb 13, 2024 (view filing)Feb 13Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$56.04−$14.0K−0.7%36.8K after10b5-1
Mar 6, 2024 (view filing)Mar 42 daysPera Antonio RDirectorSSale−7.00K$65.20−$456.4K−20.8%26.6K after
Mar 6, 2024 (view filing)Mar 51 dayMutz ChristopherHEAD OF RARE DISEASESSale−5.00K$66.00−$330.0K−5.4%87.4K after
Mar 7, 2024 (view filing)Mar 7Same dayMarken James G.SVP OPS & PROD DEVSSale−24.3K$66.37−$1.62M−16.4%124.5K after
Mar 7, 2024 (view filing)Mar 5-72 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−40.0K$65.77−$2.63M−4.5%842.6K after3 lots10b5-1
Mar 8, 2024 (view filing)Mar 6-82 daysLalwani NikhilPRESIDENT & CEOSSale−45.3K$66.10−$2.99M−9.9%411.6K after2 lots
Mar 11, 2024 (view filing)Mar 11Same dayCarey Stephen P.SVP & CFOSSale−7.79K$65.55−$510.4K−4.2%177.7K after
Mar 11, 2024 (view filing)Mar 83 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−10.0K$67.17−$671.7K−1.2%832.6K after10b5-1
Mar 13, 2024 (view filing)Mar 112 daysGassert ChadSVP - CORP. DEV. & STRATEGYSSale−20.0K$65.81−$1.32M−6.8%273.2K after10b5-1
Mar 13, 2024 (view filing)Mar 13Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$66.54−$16.6K−0.4%60.0K after10b5-1
Apr 2, 2024 (view filing)Apr 11 dayGassert ChadSVP - CORP. DEV. & STRATEGYSSale−20.0K$67.25−$1.34M−7.3%253.2K after10b5-1